A machine learning-based radiomics model for prediction of tumor mutation burden in gastric cancer
出版年份 2023 全文链接
标题
A machine learning-based radiomics model for prediction of tumor mutation burden in gastric cancer
作者
关键词
-
出版物
Frontiers in Genetics
Volume 14, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-11-06
DOI
10.3389/fgene.2023.1283090
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
- (2023) Xiao-Peng Duan et al. Frontiers in Oncology
- Radiomics Model for Predicting TP53 Status Using CT and Machine Learning Approach in Laryngeal Squamous Cell Carcinoma
- (2022) Ruxian Tian et al. Frontiers in Oncology
- Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
- (2022) Keun-Wook Lee et al. CLINICAL CANCER RESEARCH
- A multiphase contrast-enhanced CT radiomics model for prediction of human epidermal growth factor receptor 2 status in advanced gastric cancer
- (2022) Tingting Ma et al. Frontiers in Genetics
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- Radiomic machine learning for predicting prognostic biomarkers and molecular subtypes of breast cancer using tumor heterogeneity and angiogenesis properties on MRI
- (2021) Ji Young Lee et al. EUROPEAN RADIOLOGY
- Application of artificial intelligence-driven endoscopic screening and diagnosis of gastric cancer
- (2021) Yu-Jer Hsiao et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole‐slide images
- (2020) Akira Ono et al. Cancer Medicine
- Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients
- (2020) Lan Song et al. Frontiers in Oncology
- A CT-based Radiomics Model for Prediction of Lymph Node Metastasis in Early Stage Gastric Cancer
- (2020) Xujie Gao et al. ACADEMIC RADIOLOGY
- Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
- (2020) Mairéad G. McNamara et al. CANCER TREATMENT REVIEWS
- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
- (2019) Saori Mishima et al. Journal for ImmunoTherapy of Cancer
- Artificial intelligence in cancer imaging: Clinical challenges and applications
- (2019) Wenya Linda Bi et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Predicting Response to Cancer Immunotherapy using Non-invasive Radiomic Biomarkers
- (2019) S Trebeschi et al. ANNALS OF ONCOLOGY
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
- (2019) F Wang et al. ANNALS OF ONCOLOGY
- Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
- (2019) Martin Reck et al. EUROPEAN JOURNAL OF CANCER
- Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives
- (2018) Julien Taieb et al. CANCER TREATMENT REVIEWS
- Repeatability and reproducibility of radiomic features: A systematic review
- (2018) Alberto Traverso et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes
- (2018) Simona De Rosa et al. Cancers
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- CT-based radiomics signature for differentiating Borrmann type IV gastric cancer from primary gastric lymphoma
- (2017) Zelan Ma et al. EUROPEAN JOURNAL OF RADIOLOGY
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor neoantigens: building a framework for personalized cancer immunotherapy
- (2015) Matthew M. Gubin et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
- (2014) Hugo J. W. L. Aerts et al. Nature Communications
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now